Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA

Published:2020-01-16 Issue:8 Volume:35 Page:1302-1306
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Lim Ming Han¹^ORCID,Aluzaite Kristina²,Schultz Michael²³,Casey Paul¹

Affiliation:

1. Department of GastroenterologyMiddlemore Hospital, Counties Manukau District Health Board Auckland New Zealand

2. Department of Medicine, Dunedin School of MedicineUniversity of Otago Dunedin New Zealand

3. Gastroenterology UnitDunedin Public Hospital, Southern District Health Board Dunedin New Zealand

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.14964

Reference22 articles.

1. High incidence of Crohnʼs disease in Canterbury, New Zealand: Results of an epidemiologic study

2. Rising Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand

3. Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis

4. Biologics in inflammatory bowel disease: what are the data?

5. Review article: loss of response to anti-TNF treatments in Crohn’s disease

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observational Study to Compare Biological Drug Concentration Quantification Techniques and Immunogenicity in Patients with Immune-Mediated Diseases;Biomedicines;2024-04-10

2. Infliximab monitoring in Crohn’s disease: a neural network approach for evaluating disease activity and immunogenicity;Therapeutic Advances in Gastroenterology;2024-01

3. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA;Pharmaceutics;2023-11-11

4. Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting;Diagnostics;2023-05-12

5. Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay;Sensors & Diagnostics;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3